T790m Mutation - Pharma

Relevant Publications

Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis.

Issue Release: 2024

Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.

Issue Release: 2024

Case report: Sustained remission after combined sintilimab, anti-VEGF therapy, and chemotherapy in a patient with non-small cell lung cancer harboring acquired 19Del/T790M/-C797S mutation resistance.

Issue Release: 2024

Real-world study of lazertinib as second-line or greater treatment in advanced non-small cell lung cancer.

Issue Release: 2024

Development and validation of a deep learning-based model to predict response and survival of T790M mutant non-small cell lung cancer patients in early clinical phase trials using electronic medical record and pharmacokinetic data.

Issue Release: 2024

Custom-Designed Probes for the Accurate Determination of Epidermal Growth Factor Receptor Mutations and Their Allelic Configuration.

Issue Release: 2024

Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases.

Issue Release: 2024

Increased expression of SSEA-4 on TKI-resistant non-small cell lung cancer with EGFR-T790M mutation.

Issue Release: 2024

Case report: Target and immunotherapy of a lung adenocarcinoma with enteric differentiation, mutation, and high microsatellite instability.

Issue Release: 2024

Genomic heterogeneity of multiple synchronous lung cancers in Chinese population.

Issue Release: 2024

Insights into the overcoming EGFR Del19/T790M/C797S mutation: A perspective on the 2-aryl-4-aminothienopyrimidine backbone.

Issue Release: 2024

T790M mutation upconversion fluorescence biosensor via mild ATRP strategy and site-specific DNA cleavage of restriction endonuclease.

Issue Release: 2024

The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non-small cell lung cancer: A meta-analysis.

Issue Release: 2024

Droplet Digital PCR as a Molecular Tool for the Detection of the T790M Mutation in NSCLC Patients with the Activating Mutations.

Issue Release: 2024

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.

Issue Release: 2024

Detection of Single Nucleotide Polymorphisms of Circulating Tumor DNA by Strand Displacement Amplification Coupled with Liquid Chromatography.

Issue Release: 2024

A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer.

Issue Release: 2024

Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation.

Issue Release: 2024

Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms-An In Vitro Study.

Issue Release: 2024

Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.

Issue Release: 2024

How Can Technology Aid in Patient Education?

What Are the Therapeutic Approaches to Mitigate Cellular Stress?

What are the Implications for Pharma Companies?

What are Adverse Drug Events?

How Does Cellular Stress Impact Drug Development?

How Does the Patent System Affect Generic Competition?

What are the Phases of Clinical Trials?

What is Medication Management?

What Causes Adverse Drug Events?

What is Medication Adherence?

T790m Mutation - Pharma

Relevant Publications

Partnered Content Networks

Relevant Topics